0001493152-24-004490.txt : 20240131 0001493152-24-004490.hdr.sgml : 20240131 20240131160525 ACCESSION NUMBER: 0001493152-24-004490 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240126 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240131 DATE AS OF CHANGE: 20240131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: bioAffinity Technologies, Inc. CENTRAL INDEX KEY: 0001712762 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 465211056 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41463 FILM NUMBER: 24582897 BUSINESS ADDRESS: STREET 1: 22211 WEST INTERSTATE-10 STREET 2: SUITE 1206 CITY: SAN ANTONIO STATE: TX ZIP: 78257 BUSINESS PHONE: 210-698-5334 MAIL ADDRESS: STREET 1: 22211 WEST INTERSTATE-10 STREET 2: SUITE 1206 CITY: SAN ANTONIO STATE: TX ZIP: 78257 8-K 1 form8-k.htm
false 0001712762 0001712762 2024-01-26 2024-01-26 0001712762 BIAF:CommonStockParValue.007PerShareMember 2024-01-26 2024-01-26 0001712762 BIAF:TradeableWarrantsToPurchaseCommonStockMember 2024-01-26 2024-01-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 26, 2024

 

BIOAFFINITY TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41463   46-5211056
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification Number)

 

22211 W Interstate 10

Suite 1206

San Antonio, Texas 78257

(210) 698-5334

(Address of principal executive offices and Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $.007 per share   BIAF   The Nasdaq Stock Market LLC
Tradeable Warrants to purchase Common Stock   BIAFW   The Nasdaq Stock Market LLC

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Management Incentive Bonus Plan

 

On January 26, 2024, the Compensation Committee of Bioaffinity Technologies, Inc. (the “Company”) adopted the Bioaffinity Technologies, Inc. Management Incentive Bonus Plan (the “Plan”). The purpose of the Plan is to align officers’ and other employees’ efforts with the strategic goals of the Company through competitive annual incentive opportunities. The Plan will be administered by the Compensation Committee of the Company’s Board of Directors. The Compensation Committee will have the power to grant awards under the Plan, determine the amount of cash and/or equity to be paid pursuant to each award and the terms and conditions of each award. Awards may provide for payment in installments, or upon the satisfaction of qualitative performance standards or quantitative performance standards, on an individual, divisional or Company-wide basis, as determined by the Compensation Committee. Equity awards will be issued in accordance with, and pursuant to, the Company’s Amended and Restated 2014 Equity Incentive Plan, as amended and/or any other equity-related incentive plan maintained by the Company.

 

Each participant in the Plan will be entitled to receive payment of the award for a Plan year only after certification by the Compensation Committee that the targets associated with such award have been satisfied. Final payments with respect to awards will vary based on the level of achievement measured against the pre-determined performance measures. Except as may be approved by the Compensation Committee, each participant must be employed full-time on the date of payment, and not under a notice of termination, to receive the amount earned under the award. Except as otherwise provided by the Compensation Committee, awards will be paid on or before March 15th following the end of the Plan year in which payment under the award is earned. The Compensation Committee will have the discretion to reduce or eliminate the amount otherwise payable to a participant if it determines that such a reduction or elimination is in the best interests of the Company. 

 

The foregoing description of the Plan does not purport to be complete and is qualified in its entirety by reference to the Plan which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

 

Executive Compensation

 

On January 26, 2024, the Compensation Committee approved discretionary bonuses for each of Maria Zannes, Vivienne Rebel, Michael Dougherty, Timothy Zannes, Xavier Reveles and Steven Girgenti for calendar year 2023 of $75,000, $100,000, $100,000, $21,000, $52,500 and $37,500, respectively to be paid 50% in cash and 50% in shares of restricted stock. The bonuses shall be paid out on or before January 31, 2024. The number of shares of restricted stock to be issued shall be determined by dividing the cash value of 50% of each executive’s bonus by the closing price of the Company’s common stock on January 31, 2024.

 

In addition, the Compensation Committee approved an amendment (the “Amendment”) to Mr. Dougherty’s offer letter to amend the terms of a restricted stock award previously granted to Mr. Dougherty pursuant to his offer letter (the “Prior Restricted Stock Award”). The Amendment provides that upon a Change in Control (as defined in the Company’s Amended and Restated 2014 Equity Incentive Plan, as amended), any outstanding and unvested portion of the Prior Restricted Stock Award shall vest in full immediately prior to such Change in Control. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment which is attached hereto as Exhibit 10.2 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

  Exhibit
No.
  Description
  10.1   Bioaffinity Technologies, Inc. Management Incentive Bonus Plan
  10.2   Amendment to Michael Dougherty Offer Letter
  104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIOAFFINITY TECHNOLOGIES, INC.
   
  By: /s/ Maria Zannes
    Maria Zannes
    President and Chief Executive Officer

 

Dated: January 31, 2024

 

 

EX-10.1 2 ex10-1.htm

 

Exhibit 10.1

 

bioAffinity Technologies, Inc.

 

MANAGEMENT INCENTIVE BONUS PLAN

 

  1. BACKGROUND AND PURPOSE

 

bioAffinity Technologies, Inc., a Delaware corporation, hereby adopts the Management Incentive Bonus Plan (the “Plan”), effective as provided in Paragraph 10. The purpose of the Plan is to align officers’ and other employees’ efforts with the strategic goals of the Company through competitive annual incentive opportunities.

 

  2. DEFINITIONS

 

Under the Plan, except where the context otherwise indicates, the following definitions apply:

 

(a) “Affiliate” means, with respect to any Person, any other person that, directly or indirectly, is in control of, is controlled by, or is under common control with, such Person. For purposes of this definition, the term “control,” including its correlative terms “controlled by” and “under common control with,” mean, with respect to any Person, the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise.

 

(b) “Award” means a cash and/or equity bonus award granted under the Plan. The equity awards will be issued in accordance with, and pursuant to, the bioAffinity Technologies, Inc. Amended and Restated 2014 Equity Incentive Plan, as amended and/or any other equity-related incentive plan maintained by the Company. Except as otherwise provided by the Committee, an Award shall be expressed as the percentage of a Participant’s base salary payable for a Plan Year that shall become payable if the Targets established by the Committee are satisfied. The portion of an Award that shall be payable to a Participant shall be determined by the Committee in accordance with the rules established for the Award for each Plan Year.

 

(c) “Board” means the Board of Directors of the Company.

 

(d) “Change in Control” means:

 

(i) Except as provided in Paragraph 2(d)(ii), “Change in Control” means (A) a change within a twelve-month period in the holders of more than 50% of the outstanding voting stock of the Company; or (B) any other events deemed to constitute a “change in control” by the Committee.

 

(ii) With respect to the distribution of amounts subject to an Award that constitute “deferred compensation” (within the meaning of Section 409A), the term “Change in Control” shall mean any transaction or series of transactions that constitutes a change in the ownership or effective control or a change in the ownership of a substantial portion of the assets of the Company, within the meaning of Section 409A.

 

(e) “Committee” means the Compensation Committee of the Board, provided that all references to the Committee shall be treated as references to the Committee’s delegate with respect to any Award granted within the scope of the delegate’s authority pursuant to Paragraph 3(e).

 

(f) “Company” means bioAffinity Technologies, Inc., a Delaware corporation, including any successor thereto by merger, consolidation, acquisition of all or substantially all the assets thereof, or otherwise.

 

(g) “Date of Grant” means the date on which an Award is granted.

 

(h) “Disability” means:

 

(i) A Participant’s substantial inability to perform the Participant’s employment duties due to partial or total disability or incapacity resulting from a mental or physical illness, injury or other health-related cause for a period of twelve (12) consecutive months or for a cumulative period of fifty-two (52) weeks in any twenty-four (24) consecutive-month period; or

 

(ii) If more favorable to the Participant, “Disability” as it may be defined in such Participant’s employment agreement between the Participant and the Company or an Affiliate, if any.

 

(i) “Eligible Employee” means an employee of the Company or an Affiliate, as determined by the Committee.

 

 
 

 

(j) “Participant” means an Eligible Employee who is granted an Award.

 

(k) “Person” means an individual, a corporation, a partnership, an association, a trust or any other entity or organization.

 

(l) “Plan” means this Management Incentive Bonus Plan as set forth herein, and as amended from time to time.

 

(m) “Plan Year” means the Company’s fiscal year.

 

(n) “Qualitative Performance Standards” means performance standards other than Quantitative Performance Standards, including but not limited to customer service, management effectiveness, workforce diversity and other Qualitative Performance Standards relevant to the Company’s business, as may be established by the Committee, and the achievement of which shall be determined in the discretion of the Committee.

 

(o) “Quantitative Performance Standards” means performance standards such as (a) income; (b) expense; (c) operating cash flow; (d) capital spending; (e) total shareholder return, (f) gross margin; (g) growth in revenues, sales, market share, gross income, net income, pre-tax income, stock price, and/or earnings per share, return on assets, net assets, and/or capital, working capital, free cash flow and/or after tax cash flow, earnings before interest and taxes (EBIT), earnings before interest, taxes, depreciation, and amortization (EBITDA); (h) EBITDA plus stock compensation; (i) return on shareholders’ equity, return on invested capital (j) economic or shareholder value added, acquisition of assets, (k) acquisition of companies; (l) creation of new joint ventures; (m) growth in new products; (n) lower product acquisition costs and/or improvements in costs and/or expenses, (o) stock price hurdles; (p) research and development of product lines in the pipeline; (q) publications in peer-reviewed journals and presentations at scientific and medical conferences; and (r) other objective financial or service-based standards relevant to the Company’s business as may be established by the Committee. The performance standards may be measured relative to a peer group, an index or a business plan and may be considered as absolute measures or changes in measures, relative to a pre-established target or to a previous year’s results, in each case as specified by the Committee.

 

(p) “Section 16(b) Officer” means an officer of the Company who is subject to the short-swing profit recapture rules of Section 16(b) of the 1934 Act.

 

(q) “Target” means, for any Plan Year, the Qualitative Performance Standards and the Quantitative Performance Standards established by the Committee, in its discretion. Qualitative Performance Standards, Quantitative Performance Standards and the weighting of such Standards may differ from Plan Year to Plan Year, and within a Plan Year, may differ among Participants or classes of Participants.

 

(r) “Terminating Event” means any of the following events:

 

(i) the liquidation of the Company; or

 

(ii) a Change in Control.

 

  3. ADMINISTRATION OF THE PLAN

 

(a) Administration. The Plan shall be administered by the Committee. The Committee shall have the power and duty to do all things necessary or convenient to effect the intent and purposes of the Plan and not inconsistent with any of the provisions hereof, whether or not such powers and duties are specifically set forth herein, and, by way of amplification and not limitation of the foregoing, the Committee shall have the power to:

 

(i) provide rules and regulations for the management, operation and administration of the Plan, and, from time to time, to amend or supplement such rules and regulations;

 

(ii) construe the Plan, which construction, as long as made in good faith, shall be final and conclusive upon all parties hereto;

 

(iii) correct any defect, supply any omission, or reconcile any inconsistency in the Plan in such manner and to such extent as it shall deem expedient to carry the same into effect, and it shall be the sole and final judge of when such action shall be appropriate; and

 

(iv) determine whether the conditions to the payment of a bonus pursuant to an Award have been satisfied.

 

The resolution of any questions with respect to payments and entitlements pursuant to the provisions of the Plan shall be determined by the Committee, and all such determinations shall be final and conclusive.

 

(b) Grants. Subject to the express terms and conditions set forth in the Plan, the Committee shall have the power, from time to time, to select those Eligible Employees to whom Awards shall be granted under the Plan, to determine the amount of cash and/or equity to be paid pursuant to each Award, and, pursuant to the provisions of the Plan, to determine the terms and conditions of each Award.

 

 
 

 

(c) Exculpation. No member of the Committee shall be personally liable for monetary damages for any action taken or any failure to take any action in connection with the administration of the Plan or the granting of Awards thereunder unless (i) the member of the Committee has breached or failed to perform the duties of the office, and (ii) the breach or failure to perform constitutes self-dealing, willful misconduct or recklessness; provided, however, that the provisions of this Paragraph 3(c) shall not apply to the responsibility or liability of a member of the Committee pursuant to any criminal statute.

 

(d) Indemnification. Service on the Committee shall constitute service as a member of the Board. Each member of the Committee shall be entitled without further act on the member’s part to indemnity from the Company to the fullest extent provided by applicable law and the Company’s Certificate of Incorporation and Bylaws in connection with or arising out of any action, suit or proceeding with respect to the administration of the Plan or the granting of Awards thereunder in which the person may be involved by reason of the person’s being or having been a member of the Committee, whether or not the person continues to be such member of the Committee at the time of the action, suit or proceeding.

 

(e) Delegation of Authority. The Committee may delegate its authority with respect to the grant, amendment, interpretation and administration of Awards, other than Awards to Section 16(b) Officers, to a person, persons or committee, in its sole and absolute discretion. Actions taken by the Committee’s duly-authorized delegate shall have the same force and effect as actions taken by the Committee. Any delegation of authority pursuant to this Paragraph 3(e) shall continue in effect until the earliest of:

 

(i) such time as the Committee shall, in its sole and absolute discretion, revoke such delegation of authority;

 

(ii) in the case of delegation to a person that is conditioned on such person’s continued service as an employee of the Company or as a member of the Board, the date such delegate shall cease to serve in such capacity for any reason; or

 

(iii) the delegate shall notify the Committee that he or she declines to continue to exercise such authority.

 

(f) Participant Information. The Company shall furnish to the Committee in writing all Participant information the Company deems appropriate for the Committee to exercise its powers and duties in administration of the Plan. Such information shall be conclusive for all purposes of the Plan and the Committee shall be entitled to rely thereon without any investigation thereof; provided, however, that the Committee may correct any errors discovered in any such information.

 

  4. ELIGIBILITY

 

Awards may be granted only to Eligible Employees of the Company and its Affiliates, as determined by the Committee. No Awards shall be granted to an individual who is not an Eligible Employee of the Company or an Affiliate of the Company.

 

  5. AWARDS

 

The terms and conditions of Awards shall be as determined from time to time by the Committee, consistent, however, with the following:

 

(a) Time of Grant. Awards may be granted at any time from the date of adoption of the Plan by the Committee until the Plan is terminated by the Board or the Committee.

 

(b) Non-uniformity of Awards. The provisions of Awards need not be the same with respect to each Participant.

 

(c) Establishment of Targets and Conditions to Payment of Awards.

 

(i) Except as otherwise provided by the Committee, Awards shall be expressed as a percentage of a Participant’s base salary.

 

(ii) The Committee shall establish such conditions on the payment of a bonus pursuant to an Award as it may, in its sole discretion, deem appropriate.

 

(iii) The Award may provide for the payment of Awards in installments, or upon the satisfaction of Qualitative Performance Standards or Quantitative Performance Standards, on an individual, divisional or Company-wide basis, as determined by the Committee.

 

(iv) Each Participant shall be entitled to receive payment of the Award for a Plan Year only after certification by the Committee that the Targets associated with the Award as established by the Committee for such Plan Year have been satisfied. Final payments with respect to Awards will vary based on the level of achievement measured against the pre-determined performance measures.

 

(v) Except as provided in Paragraph 5(e)(ii) or as may be approved by the Committee, each Participant must be employed full-time on the date of payment to receive the amount earned under the Award. Except as otherwise provided by the Committee, Awards shall be paid on or before March 15th following the end of the Plan Year in which payment under the Award is earned.

 

 
 

 

(vi) For purposes of calculating whether any Quantitative Performance Standard has been met, the following effects may be eliminated: (i) extraordinary, unusual, and/or nonrecurring items of gain or loss; (ii) gains or losses on the disposition of a business; (iii) dividends declared on the Company’s stock; (iv) changes in tax or accounting principles, regulations or laws; (v) expenses incurred in connection with a merger, acquisition or similar transaction; or (vi) such other effects that the Committee may approve to be eliminated.

 

(vii) Notwithstanding the determination of the amount payable to a Participant under an Award with respect to any Plan Year under the Plan, the Committee shall have the discretion to reduce or eliminate the amount otherwise payable to a Participant if it determines that such a reduction or elimination of the amount payable is in the best interests of the Company.

 

(e) Transfer and Termination of Participant’s Employment.

 

(i) Transfer of Employment. A transfer of an Eligible Employee between two employers, each of which is the Company or an Affiliate of the Company (a “Transfer”), shall not be deemed a termination of employment. The Committee may grant Awards pursuant to which the Committee reserves the right to modify the calculation of an Award in connection with a Transfer. In general, except as otherwise provided by the Committee at the time an Award is granted or in connection with a Transfer, upon the Transfer of a Participant between Affiliates or divisions while an Award is outstanding and unexpired, the outstanding Award shall be treated as having terminated and expired, and a new Award shall be treated as having been made, effective as of the effective date of the Transfer, for the portion of the Award which had not expired or been paid, but subject to the performance and payment conditions applicable generally to Awards for Participants who are employees of the transferee Affiliate or division, all as shall be determined by the Committee in an equitable manner.

 

(ii) Termination of Employment. The Committee, in its sole and absolute discretion and to the extent permitted under and in accordance with Section 409A, may, but is not required to, make a full or pro-rated payment to a Participant for a Plan Year in the event of the Participant’s death, Disability, retirement, or termination of employment during the Plan Year or after the end of the Plan Year; provided, that payments shall only be made on the earlier of (i) the death or Disability of the Participant or (ii) the payment date established under Paragraph 5(c)(v).

 

(f) Maximum Grant. In no event shall the amount paid to any Participant pursuant to an Award for any Plan Year exceed $2 million.

 

  6. TERMINATING EVENTS

 

The Committee shall give Participants at least thirty (30) days’ notice (or, if not practicable, such shorter notice as may be reasonably practicable) prior to the anticipated date of the consummation of a Terminating Event. The Committee may, in its discretion, provide in such notice that upon the consummation of such Terminating Event, any remaining conditions to payment of a Participant’s Award shall be waived, in whole or in part.

 

  7. AMENDMENT AND TERMINATION

 

The Company reserves the right in its Board (or a duly authorized committee thereof) to amend, suspend or terminate the Plan or to adopt a new plan in place of this Plan at any time. Furthermore, no amendment, suspension or termination shall, without the consent of the Participant, alter or impair a Participant’s right to receive payment of the amount earned pursuant to an Award and payable hereunder without the written consent of the Participant.

 

  8. MISCELLANEOUS PROVISIONS

 

(a) Unsecured Creditor Status. A Participant entitled to payment of an Award hereunder shall rely solely upon the unsecured promise of the Company, as set forth herein, for the payment thereof, and nothing herein contained shall be construed to give to or vest in a Participant or any other person now or at any time in the future, any right, title, interest, or claim in or to any specific asset, fund, reserve, account, insurance or annuity policy or contract, or other property of any kind whatever owned by the Company, or in which the Company may have any right, title, or interest, nor or at any time in the future.

 

(b) Non-Assignment of Awards. No amount potentially payable under this Plan nor any right or benefit under this Plan shall be subject to anticipation, alienation, sale, assignment, pledge, encumbrance, garnishment, execution or levy of any kind or charge before the date on which payment is made, and any attempt to anticipate, alienate, sell, assign, pledge, encumber and to the extent permitted by applicable law, charge, garnish, execute upon or levy upon the same shall be void and shall not be recognized or given effect by the Company. Except as expressly provided by the Committee, the rights and benefits under the Plan shall not be transferable or assignable other than by will or the laws of descent and distribution.

 

(c) Other Company Plans. It is agreed and understood that any benefits under this Plan are in addition to any and all benefits to which a Participant may otherwise be entitled under any other contract, arrangement, or voluntary pension, profit sharing or other compensation plan of the Company, whether funded or unfunded, and that this Plan shall not affect or impair the rights or obligations of the Company or a Participant under any other such contract, arrangement, or voluntary pension, profit sharing or other compensation plan.

 

(d) Separability. If any term or condition of the Plan shall be invalid or unenforceable to any extent or in any application, then the remainder of the Plan, with the exception of such invalid or unenforceable provision, shall not be affected thereby, and shall continue in effect and application to its fullest extent.

 

 
 

 

(e) Continued Employment. Neither the establishment of the Plan, any provisions of the Plan, nor any action of the Committee shall be held or construed to confer upon any Participant the right to a continuation of employment by the Company. The Company reserves the right to dismiss any employee (including a Participant), or otherwise deal with any employee (including a Participant) to the same extent as though the Plan had not been adopted.

 

(f) Incapacity. If the Committee determines that a Participant is unable to care for his affairs because of illness or accident, any benefit due such Participant under the Plan may be paid to his spouse, child, parent, or any other person deemed by the Committee to have incurred expense for such Participant (including a duly appointed guardian, committee, or other legal representative), and any such payment shall be a complete discharge of the Company’s obligation hereunder.

 

(g) Reporting and Withholding. The Company shall have the right to make such provisions as it deems necessary or appropriate to satisfy any obligations it may have to withhold federal, state and/or local income or other taxes incurred by reason of payments pursuant to the Plan or to report any amounts paid or payable under this Plan.

 

(h) Application of Company Clawback Policy. All Awards under the Plan shall be subject to the provisions of any clawback or recoupment policy approved by the Board and/or Committee, as such policy may be in effect from time to time.

 

  9. GOVERNING LAW

 

The Plan and all determinations made and actions taken pursuant to the Plan shall be governed in accordance with Delaware law.

 

  10. EFFECTIVE DATE

 

The Plan is effective for bonus awards granted on or after January 26, 2024.

 

 

EX-10.2 3 ex10-2.htm

 

Exhibit 10.2

 

AMENDMENT TO OFFER LETTER

 

This Amendment (this “Amendment”), effective as of the 26th day of January 2024, to the Offer Letter, dated April 11, 2023 (the “Offer Letter”), by and between bioAffinity Technologies, Inc. (the “Company”) and Michael Dougherty (“Dougherty”). Capitalized terms used herein without definition shall have the meanings assigned in the Offer Letter.

 

WHEREAS, the Company and Dougherty desire to amend the Offer Letter to provide that the equity award issued to Dougherty pursuant thereto will vest in full upon a Change in Control (as defined in the Company’s 2014 Equity Incentive Plan, as amended).

 

NOW THEREFORE, in consideration of the premises and the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree to amend the Offer Letter as follows:

 

1. Amendment. The following shall be inserted prior to the penultimate sentence in the fourth paragraph of the Offer Letter:

 

“Notwithstanding anything herein to the contrary, the Equity Grant will vest (meaning the restrictions on the restricted stock will lapse) in full upon and immediately prior to a Change in Control (as defined in the Company’s 2014 Equity Incentive Plan, as amended).”

 

2. Severability. The provisions of this Amendment are severable and if any part of it is found to be unenforceable the other paragraphs shall remain fully valid and enforceable.

 

3. No Other Amendments; Confirmation. All other terms of the Agreement shall remain in full force and effect. The Agreement, as amended by this Amendment, constitutes the entire agreement between the parties with respect to the subject matter thereof.

 

4. Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original but both of which together shall constitute one and the same instrument.

 

5. Governing Law. This Amendment is made and shall be construed and performed under the laws of the State of Texas without regard to its choice or conflict of law principles and the parties agree to Texas as the exclusive venue for any disputes arising hereunder.

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to the Offer Letter to be duly executed as of the day and year first above written.

 

  BIOAFFINITY TECHNOLOGIES, INC.
     
  By: /s/ Maria Zannes
  Name: Maria Zannes
  Title: President and Chief Executive Officer
     
  By: /s/ Michael Dougherty
    Michael Dougherty

 

 

EX-101.SCH 4 biaf-20240126.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 biaf-20240126_def.xml XBRL DEFINITION FILE EX-101.LAB 6 biaf-20240126_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock Par Value. 007 Per Share [Member] Tradeable Warrants To Purchase Common Stock [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 biaf-20240126_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Jan. 26, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 26, 2024
Entity File Number 001-41463
Entity Registrant Name BIOAFFINITY TECHNOLOGIES, INC.
Entity Central Index Key 0001712762
Entity Tax Identification Number 46-5211056
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 22211 W Interstate 10
Entity Address, Address Line Two Suite 1206
Entity Address, City or Town San Antonio
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78257
City Area Code 210
Local Phone Number 698-5334
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock Par Value. 007 Per Share [Member]  
Title of 12(b) Security Common Stock, par value $.007 per share
Trading Symbol BIAF
Security Exchange Name NASDAQ
Tradeable Warrants To Purchase Common Stock [Member]  
Title of 12(b) Security Tradeable Warrants to purchase Common Stock
Trading Symbol BIAFW
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( *N /U@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "K@#]8:&=E%N\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O:15D=#E9<,G!<&!XEM(;EM8TX;DI-VW-ZU;A^@'\#%W__SN M=W"-"=+T$5]B'S"2PW0S^K9+TH05.Q %"9#, ;U.94YTN;GKH]>4GW$/09NC MWB-4G-^#1])6DX8)6(2%R%1CC301-?7QC+=FP8?/V,XP:P!;]-A1 E$*8&J: M&$YCV\ 5,,$(HT_?!;0+<:[^B9T[P,[),;DE-0Q#.=1S+N\@X/WYZ75>MW!= M(MT9S+^2DW0*N&*7R6_U>K-]9*KBU6W!15&+;24DOY/BX6-R_>%W%?:]=3OW MCXTO@JJ!7W>AO@!02P,$% @ JX _6)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" "K@#]8/C#>?P<% "?% & 'AL+W=O+XB?]N^?=E>[LBXV2C^:->>6/,>1-)>UM;7)>;UN@C6/F3E5 M"9=P9ZETS"RA?9M:GN7:C41D+RJ28FC6.F M7ZYXI#:7-;_V>N%>K-;67:CW+A*VXC-N/R=3#6?U7"44,9=&*$DT7U[6^O[Y M5<-S!MD37P3?F#?'Q UEH=2C.QF'ES7/$?&(!]9),/AYX@,>14X).+[N1&OY M.YWAV^-7]5$V>!C,@AD^4-&#".WZLM:MD9 O61K9>[7YR'<#:CF]0$4F^T\V MVV=;C1H)4F-5O#,&@EC([2][WCGBC4&SN\> [@QHQKU]449YS2SK76BU(=H] M#6KN(!MJ9@UP0KJHS*R&NP+L;&^@GKB^J%N0UC M0CW:_-:\#@0Y!LTQ:*;7V*-WK8(48FW)_"7A93BX>??D$P+1R"$:J$H?",*, M8A2Q51D%;K]DD>$(1S/G:![FC"G70H5D*$,"P2WU"ZZ4AZDJ3JT?]+TF^T&PM/.>=J'\-SSE3!6,_#9A,6ECL)UKL9W M_=%H/!G/_SR:#PR3@$-K$4 V2%X8QDHG2B=D1V3F87)0)0F Y6".\&K*BR-.2Y^/40(?:\HH-XAC/TP MU-R8X]<#<@//D3M9"E8A22EX\.@!QFVY-MEH?0^#?5/M_>^'G6]4*2PN.4N% MY4<^];" ^T4C\/%2_IYPX,X@UG.UD:5TN-R,R:.^M$H*A>$5+<+':_Q[O#P7 MIUH]"1F4AQO7G/^!H15=P\>+_7NTJ8+4BDU6A@#=4O&H./U_,' M+:SE$AP3QZGIY"FZ M@(]7ZJGF)P&XA\/\VJX28:'&-;E;+O?$#]>K(J-%\:=XI?X/V=B8%,BJ "MD M*P&+@D\/*OC#F.N5B^<'4+!KEVP)DZ6KCPI!JU.4[,V*OZ+0NP\S'I*)@G@J M\MEP8M><#)^M\UU(YK"<,R);BVS7P:6P^#LJ_5C4?8K7:#<[@61F5?!(IDR3 M+RQ*^2GQO([#([,UTYS\?_ M[?V*#:#H#A2OY7-A8I%!XRC, 5]JZXHC 7^:.8Y* /YZ< M/\B/I\XA"3C$.(=@Y$7OH'CIAT0(7>K.7N*%*BU$%0)7X_X((RF:!\7K_JO3 M($F#-9,KOO=KHT)HTI]=]W_'F(KV0?&J[[S#V0)B^\"T^P(R;C9-4PV$,*6^ MR5LT/='7?&]Z%BV'XLWB_Z1GA=*K0[(,S9UB%4G*G(+1%PV*X@WE@!3%!5R* M/F!;&$5':N"MX_ 8DC$EZ#DG79@.NKM;MCVQ*HD MVX%:*&M5G!VN.41)NP?@_E(I^WKB-K7R/OU!+ P04 " "K@#]8X/0Z MB:H" P# #0 'AL+W-T>6QE&:.9N:,9F235>/.DC\> M.7>D4U(W:WITKGZ?),WAR!5KWIB::X^4QBKFO&JKI*DM9T4#3DHFB]DL2Q03 MFFY6NE4[Y1IR,*UV:SJCR695&GVQI#08_%*F.#DQN:9;)L7>BGXM4T*>@WD! MAH.1QA+GJ? UG8.E>0[P/&C 2T(M/!;2!0*FC MZ D-8@@3%(A_'2W$O@K[]J_"DEJ,/EI>BZ_6NG/)CT>=X M=%;7\OQ!BDHK'FK_[82;%1O]R-%8\>RSP:0*:6R:O2?O1CS-.AEF\&OB;<9^L!!XK:_H5GE;RPH'L6R&= MT(-V%$7!]8NI]^$=V_O'X4U\O[[@)6NE>YK -;W(7W@A6I5/JQY@7X95%_DS MG.YY-CW3?"ZA"][Q8CNHMMKW(O&"SSI@*&<5M&D27JLT1]@E<,V?8?+$_<)_=7O-(\3],LPW9TNXTRV&+[ MEF7PC4?#N($'E@X]W&)^3U.6!>PV8'\\3PP4W&?-(6N8MRP$XPC>8XA,(OQ&-8?20$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9NMQ= M%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6S MU%L,9KD8M;:X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD M)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7? MZ/6M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U M$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0 ( *N M/U@D'INBK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.U MD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E. MGV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S M9)[NF:*'3^ 5!+ P04 M" "K@#]899!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU. MPS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^> MEZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-X MJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB] MXY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TAD MIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_ MYHOA/UY_ 5!+ 0(4 Q0 ( *N /U@'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ JX _6&AG91;O M *P( !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! M A0#% @ JX _6)E?P<% "?% M& @($." >&PO=V]R:W-H965T&UL4$L! M A0#% @ JX _6.#T.HFJ @ , P T ( !2PT 'AL M+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0# M% @ JX _6"0>FZ*M ^ $ !H ( !:1( 'AL+U]R M96QS+W=O9(9 0 MSP, !, ( !3A, %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& 2 D "0 ^ @ F!0 end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bioaffinitytech.com/role/Cover Cover Cover 1 false false All Reports Book All Reports biaf-20240126.xsd biaf-20240126_def.xml biaf-20240126_lab.xml biaf-20240126_pre.xml form8-k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "BIAF", "nsuri": "http://bioaffinitytech.com/20240126", "dts": { "schema": { "local": [ "biaf-20240126.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "biaf-20240126_def.xml" ] }, "labelLink": { "local": [ "biaf-20240126_lab.xml" ] }, "presentationLink": { "local": [ "biaf-20240126_pre.xml" ] }, "inline": { "local": [ "form8-k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "report": { "R1": { "role": "http://bioaffinitytech.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "auth_ref": [] }, "BIAF_CommonStockParValue.007PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://bioaffinitytech.com/20240126", "localname": "CommonStockParValue.007PerShareMember", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock Par Value. 007 Per Share [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "BIAF_TradeableWarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://bioaffinitytech.com/20240126", "localname": "TradeableWarrantsToPurchaseCommonStockMember", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Tradeable Warrants To Purchase Common Stock [Member]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001493152-24-004490-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-004490-xbrl.zip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form8-k_htm.xml IDEA: XBRL DOCUMENT 0001712762 2024-01-26 2024-01-26 0001712762 BIAF:CommonStockParValue.007PerShareMember 2024-01-26 2024-01-26 0001712762 BIAF:TradeableWarrantsToPurchaseCommonStockMember 2024-01-26 2024-01-26 iso4217:USD shares iso4217:USD shares false 0001712762 8-K 2024-01-26 BIOAFFINITY TECHNOLOGIES, INC. DE 001-41463 46-5211056 22211 W Interstate 10 Suite 1206 San Antonio TX 78257 210 698-5334 false false false false true Common Stock, par value $.007 per share BIAF NASDAQ Tradeable Warrants to purchase Common Stock BIAFW NASDAQ false